← TrendWatcher
arXiv cs.AI
5/10

TrialSketch

Cohort-and-outcome analyzer for clinical trial managers at small biotechs and CROs — describe a trial question, get a longitudinal, auditable analysis of patient cohorts across EHR, notes, and imaging, with ready-to-insert figures for protocols and publications.

Target user

Clinical operations leads and biostatisticians at small biotechs

Features
  • Cohort builder that fuses structured EHR fields with notes and imaging findings
  • Pre-built longitudinal analyses (time-to-event, biomarker trajectory, adverse-event patterns) for common trial questions
  • Auditable analysis log showing every transformation and assumption for regulators
  • Publication-ready figures with embedded provenance metadata
Why now

ClinLens quantifies a big gap between runnable clinical code and clinically correct analyses — trial managers need that gap closed with auditable, longitudinal tooling rather than ad-hoc Jupyter notebooks.

Signals · overall 5/10
Demand
6/10

Multiple sources confirm small biotechs struggle with statistical analysis and operational analytics, and WCG's 2025 trends report highlights this as a persistent pain area; the ClinLens benchmark itself documents a substantial gap between runnable code and clinically correct longitudinal analyses.2025 Clinical Trial Trends & InsightsHow Small Biotech Can Overcome Clinical Trial Hurdles

Whitespace
4/10

Market is crowded with established EDC/analytics suites (Medidata Rave, Veeva Vault EDC, Oracle Clinical One), EHR-native tools (Epic SlicerDicer), open OMOP/OHDSI ATLAS, and a long 2026 comparison list of trial analytics tools; no obvious white-space for an additional general cohort analyzer.Best Clinical Trial Analytics Software: 2026 ComparisonEDC Software Pricing 2026: Medidata vs Veeva vs Oracle

Monetization
6/10

Enterprise incumbents (Medidata, Veeva, Oracle) sell via custom quotes that can run into millions, and per-study pricing models on smaller EDCs (Castor, capture.study) show willingness to pay; small biotechs have tighter budgets but do pay for 21 CFR Part 11-aligned tooling, supporting a credible SaaS price point.EDC Software Pricing 2026: Medidata vs Veeva vs OracleClinical Trial Software for Small Biotech - capture.study

Longevity
7/10

Clinical trials are a structurally regulated, multi-decade industry with growing multimodal/EHR data mandates (21st Century Cures Act, FHIR, OMOP) and the U.S. EHR market projected to exceed $45B by 2028, giving the tool a long horizon if it achieves compliance and trust.EHR Software Comparison Guide 2026: Epic vs Cerner vs MEDITECH vs athenahealth

Feasibility
3/10

Building an auditable, longitudinal, multimodal clinical analyzer requires HIPAA/GDPR compliance, FHIR/OMOP integrations, validated statistical engines, and 21 CFR Part 11 audit trails — far beyond a single-developer MVP and competing against entrenched clinical platforms.Cohort Analysis Platform — Tools, Standards + Use Cases (2026)

ClinLens: Towards Long-Horizon Coding Agents for Longitudinal Multimodal Clinical Data SciencearXiv cs.AI · 2026-07-31 (today)